Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "RSE"

1932 News Found

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'
News | March 25, 2026

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'

New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis


Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
News | March 25, 2026

Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain

The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge


Roche inaugurates new research home for the Institute of Human Biology
R&D | March 24, 2026

Roche inaugurates new research home for the Institute of Human Biology

The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients


Government constitutes National Dental Commission to transform dental education
Policy | March 23, 2026

Government constitutes National Dental Commission to transform dental education

The government has appointed Dr. Sanjay Tewari as Chairperson, National Dental Commission and Dr. Mousumi Goswami, Part-Time Member, National Dental Commission


Pfizer warns shareholders against Tutanota’s mini-tender offer
News | March 21, 2026

Pfizer warns shareholders against Tutanota’s mini-tender offer

Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer


Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer
Clinical Trials | March 21, 2026

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival


Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI
Clinical Trials | March 20, 2026

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI


Pfizer drug candidate shows strong results in tough breast cancer study
Clinical Trials | March 19, 2026

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged


PsiQuantum joins forces with Japan’s National Cancer Center to revolutionize cancer research with quantum computing
R&D | March 18, 2026

PsiQuantum joins forces with Japan’s National Cancer Center to revolutionize cancer research with quantum computing

The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications